The global Retinal Vein Occlusion market gathered revenue around USD 18.2 billion in 2021 and market is set to grow USD 34.7 billion by the end of 2030 and is estimated to expand at a modest CAGR of 8.4% during the prediction period 2022 to 2030.
Growth Factors:
Retinal vein occlusion is the blockage of the retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally. A blood clot causes a blockage in the vein, which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. Rise in prevalence of eye diseases globally, increase in the geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments are the major drivers of the global retinal vein occlusion market.
North America held major share of the global retinal vein occlusion market in 2020 due to improved healthcare infrastructure, rise in prevalence of eye diseases, advanced technology, and increase in the geriatric population. The retinal vein occlusion market in Asia Pacific is likely to expand at a high CAGR of 9.6% from 2022 to 2030. Increase in incidence of eye diseases in Asia Pacific, especially in China, Singapore, Indonesia, and other countries in Southeast Asia, and rise in healthcare expenditure are expected to fuel the growth of the market in Asia Pacific from 2022 to 2030.
Report Scope of the Retinal Vein Occlusion Market
|
Report Coverage |
Details |
|
Market Size |
US$ 34.7 Billion by 2030 |
|
Growth Rate |
CAGR of 8.4% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Type, Treatment Type and Region, |
|
Companies Mentioned |
Alimera Sciences, Allergan (AbbVie, Inc.), Annexin Pharmaceuticals AB (publ), Bayer AG, Carl Zeiss AG, F. Hoffmann-La Roche Ltd., Iridex Corporation, Lumenis, Nidek Co., Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., and Topcon Corporation.. |
Retinal Vein Occlusion Market: Overview
This report analyzes the current scenario and future prospects of the global retinal vein occlusion market. Retinal vein occlusion is the blockage of the retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally. A blood clot causes a blockage in the vein, which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. Rise in prevalence of eye diseases globally, increase in geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments are the major drivers of the global retinal vein occlusion market.
The report includes an elaborate executive summary, which provides a snapshot of various segments of the global retinal vein occlusion market. It also provides information and data analysis of the global retinal vein occlusion market about segments based on type, treatment type, and region.
The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global retinal vein occlusion market
The report includes company profiles, which provide information about their business, product portfolios, strategic overview, and competition landscape in the global retinal vein occlusion market
The report on the global retinal vein occlusion market offers market attractiveness analysis of regions and segments
The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global retinal vein occlusion market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global retinal vein occlusion market.
Retinal Vein Occlusion Market: Key Segments
In terms of type, the global retinal vein occlusion market has been bifurcated into central retinal vein occlusion and branch retinal vein occlusion. The central retinal vein occlusion segment dominated the global retinal vein occlusion market in 2020, and the trend is projected to continue during the forecast period.
Based on treatment type, the global retinal vein occlusion market has been classified into anti-VEGF drugs, corticosteroid drugs, pan-retinal photocoagulation therapy, and laser therapy. The anti-VEGF drugs segment held major share of the global retinal vein occlusion market in 2020. Rise in prevalence and incidence of diabetes drives the segment.
Market size and forecast for each of these segments and sub-segments have been provided from 2017 to 2030. The CAGR of respective segment has also been provided from 2022 to 2030, considering 2020 as the base year, and 2017, 2018, and 2019 as historical years.
North America to Dominate Global Market; Asia Pacific to Offer Significant Opportunities
In terms of region, the global retinal vein occlusion market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to account for leading share of the global retinal vein occlusion market during the forecast period. The retinal vein occlusion market in Asia Pacific is projected to grow at a rapid pace in the near future. India and China are likely to be lucrative markets for retinal vein occlusion treatment during the forecast period.
Some of the prominent players in the Retinal Vein Occlusion Market include:
Alimera Sciences, Allergan (AbbVie, Inc.), Annexin Pharmaceuticals AB (publ), Bayer AG, Carl Zeiss AG, F. Hoffmann-La Roche Ltd., Iridex Corporation, Lumenis, Nidek Co., Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., and Topcon Corporation.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Retinal Vein Occlusion Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Retinal Vein Occlusion Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Retinal Vein Occlusion Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. COVID-19 Pandemic Impact on Industry (value chain and short-/ mid-/ long-term impact)
6. Global Retinal Vein Occlusion Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast by Type, 2017–2030
6.3.1. Central Retinal Vein Occlusion
6.3.2. Branch Retinal Vein Occlusion
6.4. Market Attractiveness Analysis, by Type
7. Global Retinal Vein Occlusion Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Treatment Type, 2017–2030
7.3.1. Anti-VEGF Drugs
7.3.2. Corticosteroid Drugs
7.3.3. Pan-retinal Photocoagulation Therapy
7.3.4. Laser Therapy
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Retinal Vein Occlusion Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Sub-region/Region
9. North America Retinal Vein Occlusion Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017–2030
9.2.1. Central Retinal Vein Occlusion
9.2.2. Branch Retinal Vein Occlusion
9.3. Market Value Forecast, by Treatment Type, 2017–2030
9.3.1. Anti-VEGF Drugs
9.3.2. Corticosteroid Drugs
9.3.3. Pan-retinal Photocoagulation Therapy
9.3.4. Laser Therapy
9.4. Market Value Forecast, by Country, 2017–2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Treatment Type
9.5.3. By Country
10. Europe Retinal Vein Occlusion Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2030
10.2.1. Central Retinal Vein Occlusion
10.2.2. Branch Retinal Vein Occlusion
10.3. Market Value Forecast, by Treatment Type, 2017–2030
10.3.1. Anti-VEGF Drugs
10.3.2. Corticosteroid Drugs
10.3.3. Pan-retinal Photocoagulation Therapy
10.3.4. Laser Therapy
10.4. Market Value Forecast, by Country/Sub-region, 2017–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Treatment Type
10.5.3. By Country/Sub-region
11. Asia Retinal Vein Occlusion Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2030
11.2.1. Central Retinal Vein Occlusion
11.2.2. Branch Retinal Vein Occlusion
11.3. Market Value Forecast, by Treatment Type, 2017–2030
11.3.1. Anti-VEGF Drugs
11.3.2. Corticosteroid Drugs
11.3.3. Pan-retinal Photocoagulation Therapy
11.3.4. Laser Therapy
11.4. Market Value Forecast, by Country/Sub-region, 2017–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Treatment Type
11.5.3. By Country/Sub-region
12. Latin America Retinal Vein Occlusion Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2030
12.2.1. Central Retinal Vein Occlusion
12.2.2. Branch Retinal Vein Occlusion
12.3. Market Value Forecast, by Treatment Type, 2017–2030
12.3.1. Anti-VEGF Drugs
12.3.2. Corticosteroid Drugs
12.3.3. Pan-retinal Photocoagulation Therapy
12.3.4. Laser Therapy
12.4. Market Value Forecast, by Country/Sub-region, 2017–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Treatment Type
12.5.3. By Country/Sub-region
13. Middle East & Africa Retinal Vein Occlusion Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2030
13.2.1. Central Retinal Vein Occlusion
13.2.2. Branch Retinal Vein Occlusion
13.3. Market Value Forecast, by Treatment Type, 2017–2030
13.3.1. Anti-VEGF Drugs
13.3.2. Corticosteroid Drugs
13.3.3. Pan-retinal Photocoagulation Therapy
13.3.4. Laser Therapy
13.4. Market Value Forecast, by Country/Sub-region, 2017–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Treatment Type
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Alimera Sciences
14.3.1.1. Company Description
14.3.1.2. Business Overview
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Allergan (AbbVie, Inc.)
14.3.2.1. Company Description
14.3.2.2. Business Overview
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Annexin Pharmaceuticals AB (publ)
14.3.3.1. Company Description
14.3.3.2. Business Overview
14.3.3.3. Strategic Overview
14.3.3.4. SWOT Analysis
14.3.4. Bayer AG
14.3.4.1. Company Description
14.3.4.2. Business Overview
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Carl Zeiss AG
14.3.5.1. Company Description
14.3.5.2. Business Overview
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Description
14.3.6.2. Business Overview
14.3.6.3. Financial Overview
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Iridex Corporation
14.3.7.1. Company Description
14.3.7.2. Business Overview
14.3.7.3. Financial Overview
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
14.3.8. Lumenis
14.3.8.1. Company Description
14.3.8.2. Business Overview
14.3.8.3. Strategic Overview
14.3.8.4. SWOT Analysis
14.3.9. Nidek Co., Ltd.
14.3.9.1. Company Description
14.3.9.2. Business Overview
14.3.9.3. Strategic Overview
14.3.9.4. SWOT Analysis
14.3.10. Novartis AG
14.3.10.1. Company Description
14.3.10.2. Business Overview
14.3.10.3. Financial Overview
14.3.10.4. Strategic Overview
14.3.10.5. SWOT Analysis
14.3.11. Regeneron Pharmaceuticals, Inc.
14.3.11.1. Company Description
14.3.11.2. Business Overview
14.3.11.3. Financial Overview
14.3.11.4. Strategic Overview
14.3.11.5. SWOT Analysis
14.3.12. Topcon Corporation
14.3.12.1. Company Description
14.3.12.2. Business Overview
14.3.12.3. Financial Overview
14.3.12.4. Strategic Overview
14.3.12.5. SWOT Analysis
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers